Gibbs Peter, Tie Jeanne, Bester Lourens
Department of Medical Oncology, Royal Melbourne Hospital, Parkville, Melbourne, Australia.
Interventional Radiology, Department of Medical Imaging, St Vincent's Hospital, Sydney, Australia.
Hepat Oncol. 2015 Apr;2(2):117-132. doi: 10.2217/hep.14.39. Epub 2015 Apr 20.
The incidence and impact of hepatocelluar carcinoma (HCC) continues to increase worldwide. While radical therapies such as resection, radiofrequency ablation or transplantation are potentially curative for patients with early-stage HCC, the majority of patients in routine practice present with more advanced tumors, where treatment goals are palliation and extending survival. With multiple new and promising treatment options emerging for these patients, the challenge for the medical oncologist is how best to integrate these therapies into routine clinical practice. Here we review the most recent data on the efficacy and safety of yttrium-90 radioembolization in HCC, the considerations involved in patient selection, and the optimal assessment and management of patients receiving treatment. We also examine the potential impact of several ongoing clinical trials.
肝细胞癌（HCC）的发病率及其影响在全球范围内持续上升。虽然诸如切除、射频消融或移植等根治性疗法对早期HCC患者可能具有治愈效果，但在常规临床实践中，大多数患者就诊时肿瘤已处于更晚期阶段，此时治疗目标是缓解症状并延长生存期。随着针对这些患者的多种新的、有前景的治疗选择不断涌现，肿瘤内科医生面临的挑战是如何将这些疗法最佳地整合到常规临床实践中。在此，我们综述了有关钇-90放射性栓塞治疗HCC的疗效和安全性的最新数据、患者选择时的考量因素，以及接受治疗患者的最佳评估和管理。我们还研究了几项正在进行的临床试验的潜在影响。
